US FDA accepts and grants priority review to sNDA for BRAFTOVI in combination with ERBITUX to treat BRAFV600E-mutant metastatic colorectal cancer after prior therapy

This article was originally published here

As published in The New England Journal of Medicine (NEJM), results from the BEACON CRC trial showed improvements in overall survival (OS) and objective response rates (ORR) for

The post US FDA accepts and grants priority review to sNDA for BRAFTOVI in combination with ERBITUX to treat BRAFV600E-mutant metastatic colorectal cancer after prior therapy appeared first on Pharmaceutical Business review.

0 replies

Leave a Reply

Want to join the discussion?
Feel free to contribute!

Leave a Reply